Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 21, 2025Cell TransplantationOpen Access

Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMingwei FuSNS NiuCLCan Liu

Discussion

Loading...

Member takes

Overview

Observational study assesses sBCMA as a predictive biomarker for anti-bcma car-t therapy outcomes in relapsed/refractory multiple myeloma.

Key Points

  • High sBCMA levels in bone marrow correlate with poor efficacy of anti-BCMA car-T cell therapy.
  • Patients achieving an objective response showed decreased sBCMA levels after 2 months, indicating therapy effectiveness.
  • Correlation analysis found that sBCMA levels increased again upon disease progression in patients successfully treated.
  • sBCMA serves as a potential biomarker for predicting therapy response and monitoring during long-term follow-up.

Cite This Study

Fu et al. (2025) studied this question.

synapsesocial.com/papers/68d43c8e713b0b5dfea7c88ahttps://doi.org/10.1177/09636897251374203
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  2. 2BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  3. 3Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM2025
  4. 4Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  5. 5Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy2025